2020 reported and constant currency revenue growth
2.5%
- 3.5%
Foreign Currency Exchange Impact(1)
Neutral
Adjusted Operating Profit Margin(2)
27.0%
- 28.0%
Adjusted Tax Rate(2)
16.0%
- 17.0%
Adjusted Diluted EPS(2)
$8.15
- $8.45
Free Cash Flow(2)
$1.1 - $1.3 billion
(1)
Expected to be negative in the first half of the year and slightly positive in the second half of
the year based on current foreign currency exchange rates
(2)
These measures are non-GAAP financial measures for which a reconciliation to the most
directly comparable GAAP financial measure is not available without unreasonable efforts.
See "Forward-LookingNon-GAAP Financial Measures."
Forward-LookingNon-GAAP Financial Measures
We calculate forward-lookingnon-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, we exclude the impact of certain charges related to restructuring and other cost reduction initiatives and certain legal and tax matters. We have not provided quantitative reconciliations of these forward-looking non- GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because the excluded items are not available on a prospective basis without unreasonable efforts. For example, the timing of certain transactions is difficult to predict because management's plans may change. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. It is probable that these forward-lookingnon-GAAP financial measures may be materially different from the corresponding GAAP financial measures.
Page 1 of 1
Attachments
Original document
Permalink
Disclaimer
Zimmer Biomet Holdings Inc. published this content on 04 February 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 February 2020 19:43:00 UTC
Zimmer Biomet Holdings, Inc. specializes in designing, manufacturing, and selling orthopedic and dental reconstruction implants, spinal implants, and traumatology products. Net sales break down by family of products as follows:
- reconstruction implants (57.5%): knees replacement (58.8% of net sales), hips replacement (41.2%);
- surgical products and traumatology equipment (22.1%);
- dental, spinal and craniomaxillofacial implants (12.8%);
- other (7.6%): primarily orthopedic surgery materials and instruments used during post-operative rehabilitation.
At the end of 2021, the group had approximately 30 production sites worldwide.
Net sales are distributed geographically as follows: Americas (61.3%), Europe/Middle East/Africa (21.3%) and Asia/Pacific (17.4%).